Literature DB >> 21120571

Transplantation-associated thrombotic microangiopathy after steroid pulse therapy for polyserositis related to graft-versus-host disease.

Yasunobu Ishikawa1, Saori Nishio, Hiroaki Sasaki, Risshi Kudo, Hideki Goto, Masanori Ito, Akira Suzuki, Yuichiro Fukazawa, Toshio Mochizuki, Takao Koike.   

Abstract

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a rare but devastating syndrome that occurs in allogeneic hematopoietic stem cell transplant recipients, and is associated with a variety of transplantation-related factors, including conditioning regimens, immunosuppressive agents, graft-versus-host disease (GVHD) and opportunistic infections. TA-TMA has an unfavorable prognosis and responds poorly to conventional treatment including plasma exchange (PE). We present a case of a 37-year-old man with membranous nephropathy (MN) and polyserositis caused by GVHD after hematopoietic stem cell transplantation. He developed TA-TMA after steroid pulse therapy for polyserositis. We treated the patient with PE and mycophenolate mofetil (MMF) after which the TA-TMA successfully improved and the MN underwent complete remission. The present case suggests that corticosteroids with severe GVHD might increase the risk of TA-TMA, and that PE in combination with MMF may be a valuable therapy to improve the prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21120571     DOI: 10.1007/s10157-010-0376-y

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  23 in total

1.  Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.

Authors:  Hirohisa Nakamae; Takahisa Yamane; Taro Hasegawa; Mika Nakamae; Yoshiki Terada; Kiyoyuki Hagihara; Kensuke Ohta; Masayuki Hino
Journal:  Am J Hematol       Date:  2006-07       Impact factor: 10.047

2.  Modulation of arachidonic acid metabolism in human endothelial cells by glucocorticoids.

Authors:  R De Caterina; B B Weksler
Journal:  Thromb Haemost       Date:  1986-06-30       Impact factor: 5.249

3.  Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease.

Authors:  Francisco Lopez; Pablo Parker; Auayporn Nademanee; Roberto Rodriguez; Zaid Al-Kadhimi; Ravi Bhatia; Sandra Cohen; Peter Falk; Henry Fung; Mark Kirschbaum; Amrita Krishnan; Neil Kogut; Arturo Molina; Ryotaro Nakamura; Margaret O'Donnell; Leslie Popplewell; Vinod Pullarkat; Joseph Rosenthal; Firoozeh Sahebi; Eileen Smith; David Snyder; George Somlo; Ricardo Spielberger; Anthony Stein; Robert Sweetman; Jasmine Zain; Stephen Forman
Journal:  Biol Blood Marrow Transplant       Date:  2005-04       Impact factor: 5.742

4.  Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion.

Authors:  Theresa Hahn; Arif Raza Alam; David Lawrence; Laurieann Ford; Maria R Baer; Barbara Bambach; Zale P Bernstein; Myron S Czuczman; Joaquin Silva; James L Slack; Meir Wetzler; Joanne Becker; Philip L McCarthy
Journal:  Transplantation       Date:  2004-11-27       Impact factor: 4.939

Review 5.  Impact of thrombotic thrombocytopenic purpura on leukemic children undergoing bone marrow transplantation.

Authors:  C Uderzo; M Fumagalli; P De Lorenzo; A Busca; E Vassallo; S Bonanomi; E Lanino; G Dini; S Varotto; C Messina; R Miniero; M G Valsecchi; A Balduzzi
Journal:  Bone Marrow Transplant       Date:  2000-11       Impact factor: 5.483

Review 6.  Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation.

Authors:  Vincent T Ho; Corey Cutler; Shelly Carter; Paul Martin; Roberta Adams; Mary Horowitz; James Ferrara; Robert Soiffer; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2005-08       Impact factor: 5.742

7.  Massive pericardial and pleural effusion with anasarca following allogeneic bone marrow transplantation.

Authors:  T Ueda; A Manabe; A Kikuchi; H Yoshino; Y Ebihara; T Ishii; H Yagasaki; T Mitsui; H Hisakawa; A Masunaga; K Tsuji; T Nakahata
Journal:  Int J Hematol       Date:  2000-06       Impact factor: 2.490

8.  Massive pericardial effusion complicating the course of chronic graft-versus-host disease (cGVHD) in a child with acute lymphoblastic leukemia following allogeneic bone marrow transplantation.

Authors:  A Toren; A Nagler
Journal:  Bone Marrow Transplant       Date:  1997-11       Impact factor: 5.483

Review 9.  Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease.

Authors:  A Seber; S P Khan; J H Kersey
Journal:  Bone Marrow Transplant       Date:  1996-02       Impact factor: 5.483

10.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

View more
  2 in total

Review 1.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

Review 2.  Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis.

Authors:  Joanna A Young; Christopher R Pallas; Mary Ann Knovich
Journal:  Bone Marrow Transplant       Date:  2021-04-19       Impact factor: 5.174

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.